Florian Paul Christian Binder

This inventor holds 18 USPTO granted patents and 11 published patent applications and 6 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Boehringer Ingelheim International Gmbh, Centrexion Therapeutics Corporation. Active years: 2014-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Florian Paul Christian Binder. Retrieved from https://idiyas.com/inventor/florian-paul-christian-binder

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 (Patent Applications = 11)

% Patents Active = 100.0

EPO Patents = 6 (Patent Applications = 17)

Average Co-Inventor Count = 4.1

ph-index = 4

Forward Citations = 30(Granted Patents)

Company Filing History:

12 out of 1,562

Boehringer Ingelheim International Gmbh

patents

6 out of 36

Centrexion Therapeutics Corporation

patents

Years Active: 2014-2025

Loading Chart...

Areas of Expertise:

TRPA1 Inhibitors

Tetrazoles

Thienopyrimidones

Isoxazoles

Oxadiazoles

Pyrimidinones

Uracil Derivatives

Pharmaceutical Chemistry

Chemical Compounds

Drug Development

Synthetic Chemistry

Medicinal Chemistry

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12497401 - Substituted tetrazoles as TRPA1 inhibitors (2025-12-16),

2. 12344601 - (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles (2025-07-01),

3. 12180223 - 3H,4H-thieno[2,3-d]pyrimidin-4-one derivatives as TRPA1 inhibitors (2024-12-31),

4. 11891403 - Tetrazole derivatives as TRPA1 inhibitors (2024-02-06),

5. 11884681 - 3H,4H,5H,6H,7H-pyrimido[4,5-b][1,4]oxazine-4,6-dione derivatives as TRPA1 inhibitors (2024-01-30),

6. 11884652 - Tetrazole derivatives as TRPA1 inhibitors (2024-01-30),

7. 11878981 - Substituted 1,2,4-oxadiazoles as TRPA1 inhibitors (2024-01-23),

8. 11858921 - Uracil derivatives as TRPA1 inhibitors (2024-01-02),

9. 11725004 - (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles (2023-08-15),

10. 11661430 - Tetrazole derivatives as TRPA1 inhibitors (2023-05-30),

11. 11661427 - Tetrazole derivatives as TRPA1 inhibitors (2023-05-30),

12. 11578080 - Thienopyrimidones (2023-02-14),

13. 11136336 - Thienopyrimidones (2021-10-05),

14. 11084810 - (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles (2021-08-10),

15. 10570125 - (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles (2020-02-25),

Title: Florian Paul Christian Binder - Pioneering Innovations in Medicinal Treatments

Introduction:

Florian Paul Christian Binder, a distinguished inventor based in Maselheim, DE, has made significant contributions to the field of pharmaceuticals through his inventive patents and groundbreaking research. With a total of 15 patents to his name, Binder is a leading figure in the development of novel treatments for various diseases.

Latest Patents:

Binder's recent patents showcase his expertise in developing inhibitors of the transient receptor potential ankyrin 1 (TRPA1) to address diseases that can be treated by inhibiting this protein. The patents include formulations of tetrazole derivatives and 3H,4H,5H,6H,7H-pyrimido[4,5-b][1,4]oxazine-4,6-dione derivatives, along with pharmaceutical compositions containing these compounds and processes for their preparation.

Career Highlights:

Throughout his career, Binder has worked with esteemed companies like Boehringer Ingelheim International GmbH and Centrexion Therapeutics Corporation. Through his collaborations and research efforts, he has consistently demonstrated a deep understanding of medicinal chemistry and a passion for developing innovative solutions to improve patient outcomes.

Collaborations:

Binder has had the privilege of working alongside accomplished professionals in the field, including Martin Thomas Fleck and Jens Willwacher. These collaborations have been instrumental in advancing his research and bringing his inventive ideas to fruition, ultimately benefiting the medical community and patients worldwide.

Conclusion:

Florian Paul Christian Binder's unwavering commitment to innovation and his remarkable contributions to the pharmaceutical industry underscore his status as a visionary inventor. His patents not only reflect his scientific prowess but also highlight his dedication to developing transformative therapies for challenging medical conditions. Binder's work continues to inspire and drive progress in the field of medicinal treatments, setting a high standard for future innovations in healthcare.

Profile summary based on public USPTO records.